The proteasome inhibitor velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice

Journal of Virology

Volumn 84, Issue 15, 2010, Pages 7880-7885

  Raaben, Matthijs ^a,b   Grinwis, Guy C M ^a   Rottier, Peter J M ^a   De Haan, Cornelis A M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BORTEZOMIB; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; DRUG INHIBITION; HEPATITIS; IN VITRO STUDY; MOUSE; MURINE HEPATITIS CORONAVIRUS; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BORONIC ACIDS; CORONAVIRUS INFECTIONS; HEPATITIS, VIRAL, ANIMAL; MICE; MICE, INBRED C57BL; MURINE HEPATITIS VIRUS; PROTEASE INHIBITORS; PYRAZINES; SURVIVAL ANALYSIS;

MURINE HEPATITIS VIRUS; MUS;

EID: 77954469341     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00486-10     Document Type: Article

References (52)

1. Adams, J. 2002. Development of the proteasome inhibitor PS-341. Oncologist 7:9-16.
2. Adams, J., and M. Kauffman. 2004. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 22:304-311. (Pubitemid 38725184)
3. Basler, M., C. Lauer, U. Beck, and M. Groettrup. 2009. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J. Immunol. 183:6145-6150.
4. Berges, C., H. Haberstock, D. Fuchs, M. Miltz, M. Sadeghi, G. Opelz, V. Daniel, and C. Naujokat. 2008. Proteasome inhibition suppresses essential immune functions of human CD4 T cells. Immunology 124:234-246.
5. Blanco, B., J. A. Perez-Simon, L. I. Sanchez-Abarca, X. Carvajal-Vergara, J. Mateos, B. Vidriales, N. Lopez-Holgado, P. Maiso, M. Alberca, E. Villaron, D. Schenkein, A. Pandiella, and J. San Miguel. 2006. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 107:3575-3583.
6. Chanan-Khan, A., P. Sonneveld, M. W. Schuster, E. A. Stadtmauer, T. Facon, J. L. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, R. Neuwirth, K. C. Anderson, and P. G. Richardson. 2008. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J. Clin. Oncol. 26:4784-4790.
7. Chauhan, D., T. Hideshima, C. Mitsiades, P. Richardson, and K. C. Anderson. 2005. Proteasome inhibitor therapy in multiple myeloma. Mol. Cancer Ther. 4:686-692.
8. Chen, Y. T., C. H. Lin, W. T. Ji, S. K. Li, and H. J. Liu. 2008. Proteasome inhibition reduces avian reovirus replication and apoptosis induction in cultured cells. J. Virol. Methods 151:95-100.
9. de Haan, C. A., K. Stadler, G. J. Godeke, B. J. Bosch, and P. J. Rottier. 2004. Cleavage inhibition of the murine coronavirus spike protein by a furin-like enzyme affects cell-cell but not virus-cell fusion. J. Virol. 78:6048-6054.
10. Delic, J., P. Masdehors, S. Omura, J. M. Cosset, J. Dumont, J. L. Binet, and H. Magdelenat. 1998. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br. J. Cancer 77:1103-1107. (Pubitemid 28116281)
11. DeMartino, G. N., and C. A. Slaughter. 1999. The proteasome, a novel protease regulated by multiple mechanisms. J. Biol. Chem. 274:22123-22126.
12. Desterro, J. M., M. S. Rodriguez, and R. T. Hay. 2000. Regulation of transcription factors by protein degradation. Cell Mol. Life Sci. 57:1207-1219.
13. Gao, G., J. Zhang, X. Si, J. Wong, C. Cheung, B. McManus, and H. Luo. 2008. Proteasome inhibition attenuates coxsackievirus-induced myocardial damage in mice. Am. J. Physiol. Heart Circ. Physiol. 295:H401-H408.
14. Groettrup, M., S. Khan, K. Schwarz, and G. Schmidtke. 2001. Interferongamma inducible exchanges of 20S proteasome active site subunits: why? Biochimie 83:367-372.
15. Groll, M., L. Ditzel, J. Lowe, D. Stock, M. Bochtler, H. D. Bartunik, and R. Huber. 1997. Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature 386:463-471.
16. Imajoh-Ohmi, S., T. Kawaguchi, S. Sugiyama, K. Tanaka, S. Omura, and H. Kikuchi. 1995. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem. Biophys. Res. Commun. 217:1070-1077.
17. Kane, R. C., R. Dagher, A. Farrell, C. W. Ko, R. Sridhara, R. Justice, and R. Pazdur. 2007. Bortezomib for the treatment of mantle cell lymphoma. Clin. Cancer Res. 13:5291-5294.
18. Kane, R. C., A. T. Farrell, R. Sridhara, and R. Pazdur. 2006. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin. Cancer Res. 12:2955-2960.
19. King, R. W., R. J. Deshaies, J. M. Peters, and M. W. Kirschner. 1996. How proteolysis drives the cell cycle. Science 274:1652-1659.
20. Klinger, P. P., and U. Schubert. 2005. The ubiquitin-proteasome system in HIV replication: potential targets for antiretroviral therapy. Expert Rev. Anti-Infect. Ther. 3:61-79.
21. Kropff, M., G. Bisping, E. Schuck, P. Liebisch, N. Lang, M. Hentrich, T. Dechow, N. Kroger, H. Salwender, B. Metzner, O. Sezer, M. Engelhardt, H. H. Wolf, H. Einsele, S. Volpert, A. Heinecke, W. E. Berdel, and J. Kienast. 2007. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br. J. Hematol. 138:330-337.
22. Kuo, L., G. J. Godeke, M. J. Raamsman, P. S. Masters, and P. J. Rottier. 2000. Retargeting of coronavirus by substitution of the spike glycoprotein ectodomain: crossing the host cell species barrier. J. Virol. 74:1393-1406.
23. La Frazia, S., C. Amici, and M. G. Santoro. 2006. Antiviral activity of proteasome inhibitors in herpes simplex virus-1 infection: role of nuclear factor-κB. Antivir. Ther. 11:995-1004.
24. Luo, H., J. Zhang, C. Cheung, A. Suarez, B. M. McManus, and D. Yang. 2003. Proteasome inhibition reduces coxsackievirus B3 replication in murine cardiomyocytes. Am. J. Pathol. 163:381-385.
25. Maseda, D., S. Meister, K. Neubert, M. Herrmann, and R. E. Voll. 2008. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development. Cell Death Differ. 15:600-612. (Pubitemid 351267310)
26. Nencioni, A., A. Garuti, K. Schwarzenberg, G. Cirmena, G. Dal Bello, I. Rocco, E. Barbieri, P. Brossart, F. Patrone, and A. Ballestrero. 2006. Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur. J. Immunol. 36:681-689.
27. Nencioni, A., K. Schwarzenberg, K. M. Brauer, S. M. Schmidt, A. Ballestrero, F. Grunebach, and P. Brossart. 2006. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 108: 551-558.
28. Oikawa, T., T. Sasaki, M. Nakamura, M. Shimamura, N. Tanahashi, S. Omura, and K. Tanaka. 1998. The proteasome is involved in angiogenesis. Biochem. Biophys. Res. Commun. 246:243-248.
29. Orlowski, R. Z. 1999. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ. 6:303-313.
30. Orlowski, R. Z., J. R. Eswara, A. Lafond-Walker, M. R. Grever, M. Orlowski, and C. V. Dang. 1998. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 58: 4342-4348.
31. Pahler, J. C., S. Ruiz, I. Niemer, L. R. Calvert, M. Andreeff, M. Keating, S. Faderl, and D. J. McConkey. 2003. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin. Cancer Res. 9:4570-4577.
32. Papandreou, C. N., and C. J. Logothetis. 2004. Bortezomib as a potential treatment for prostate cancer. Cancer Res. 64:5036-5043. (Pubitemid 39006513)
33. Pitts, T. M., M. Morrow, S. A. Kaufman, J. J. Tentler, and S. G. Eckhardt. 2009. Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol. Cancer Ther. 8:342-349.
34. Raaben, M., C. C. Posthuma, M. H. Verheije, E. G. te Lintelo, M. Kikkert, J. W. Drijfhout, E. J. Snijder, P. J. M. Rottier, and C. A. M. de Haan. 2010. The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle. J. Virol. 84:7869-7879.
35. Raaben, M., M. J. Groot Koerkamp, P. J. Rottier, and C. A. de Haan. 2009. Type I interferon receptor-independent and -dependent host transcriptional responses to mouse hepatitis coronavirus infection in vivo. BMC Genomics 10:350.
36. Raaben, M., H. J. Prins, A. C. Martens, P. J. Rottier, and C. A. de Haan. 2009. Non-invasive imaging of mouse hepatitis coronavirus infection reveals determinants of viral replication and spread in vivo. Cell Microbiol. 11:825-841.
37. Raaben, M., P. Whitley, D. Bouwmeester, R. A. Setterquist, P. J. Rottier, and C. A. de Haan. 2008. Improved microarray gene expression profiling of virus-infected cells after removal of viral RNA. BMC Genomics 9:221.
38. Read, M. A., A. S. Neish, F. W. Luscinskas, V. J. Palombella, T. Maniatis, and T. Collins. 1995. The proteasome pathway is required for cytokineinduced endothelial-leukocyte adhesion molecule expression. Immunity 2:493-506.
39. Rottier, P. J., M. C. Horzinek, and B. A. van der Zeijst. 1981. Viral protein synthesis in mouse hepatitis virus strain A59-infected cells: effect of tunicamycin. J. Virol. 40:350-357.
40. Satheshkumar, P. S., L. C. Anton, P. Sanz, and B. Moss. 2009. Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes. J. Virol. 83:2469-2479.
41. Schenkein, D. P. 2004. Use of proteasome inhibition in the treatment of lung cancer. Clin. Lung Cancer 6(Suppl. 2):S89-S96.
42. Shah, S. A., M. W. Potter, T. P. McDade, R. Ricciardi, R. A. Perugini, P. J. Elliott, J. Adams, and M. P. Callery. 2001. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell Biochem. 82:110-122.
43. Shinohara, K., M. Tomioka, H. Nakano, S. Tone, H. Ito, and S. Kawashima. 1996. Apoptosis induction resulting from proteasome inhibition. Biochem. J. 317(Pt. 2):385-388. (Pubitemid 26253972)
44. Si, X., G. Gao, J. Wong, Y. Wang, J. Zhang, and H. Luo. 2008. Ubiquitination is required for effective replication of coxsackievirus B3. PLoS One 3:e2585.
45. Subklewe, M., K. Sebelin-Wulf, C. Beier, A. Lietz, S. Mathas, B. Dorken, and A. Pezzutto. 2007. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum. Immunol. 68:147-155.
46. Teale, A., S. Campbell, N. Van Buuren, W. C. Magee, K. Watmough, B. Couturier, R. Shipclark, and M. Barry. 2009. Orthopoxviruses require a functional ubiquitin-proteasome system for productive replication. J. Virol. 83:2099-2108.
47. Tong, Y., J. Qian, Y. Li, H. Meng, and J. Jin. 2007. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Am. J. Hematol. 82:403-404.
48. Verheije, M. H., T. Wurdinger, V. W. van Beusechem, C. A. de Haan, W. R. Gerritsen, and P. J. Rottier. 2006. Redirecting coronavirus to a nonnative receptor through a virus-encoded targeting adapter. J. Virol. 80:1250-1260.
49. Voges, D., P. Zwickl, and W. Baumeister. 1999. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 68:1015-1068.
50. Wang, X., A. Ottosson, C. Ji, X. Feng, M. Nordenskjold, J. I. Henter, B. Fadeel, and C. Zheng. 2009. Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity. Haematologica 94:470-478.
51. Yu, G. Y., and M. M. Lai. 2005. The ubiquitin-proteasome system facilitates the transfer of murine coronavirus from endosome to cytoplasm during virus entry. J. Virol. 79:644-648.
52. Zou, P., J. Kawada, L. Pesnicak, and J. I. Cohen. 2007. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J. Virol. 81: 10029-10036.